Has Fernando Borrego received payments from drug or device companies?

Yes. Drug and device makers reported $5,370 in general payments to Fernando Borrego across 191 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Fernando Borrego did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Fernando Borrego come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Fernando Borrego

Infectious Disease · New York, NYNPI 1548288277

Payments from drug & device makers

$5,370in general payments, 2019–2025

Across 191 payments — averaging $28.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Gilead$2K
Viiv Healthcare Company$2K
AbbVie$216
Amgen$172
Paratek Pharmaceuticals, Inc.$158
Teva Pharmaceuticals USA, Inc.$63
plus $207 from 8 others

What the payments were for

Food & beverage$5,370100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Gilead	90	$2,365
Viiv Healthcare Company	53	$2,189
AbbVie	13	$216
Amgen	11	$172
Paratek Pharmaceuticals, Inc.	11	$158
Teva Pharmaceuticals USA, Inc.	2	$63
Indivior Inc.	2	$43
Vanda Pharmaceuticals Inc.	2	$41
Lundbeck LLC	2	$33
Alkermes, Inc.	1	$23
EMD Serono, Inc.	1	$21
Otsuka America Pharmaceutical, Inc.	1	$20
Melinta Therapeutics, LLC	1	$15
GSK	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,370 in reported general payments places this provider in the 75th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala	52	$200,412
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf	15	$66,107
JulucaDolutegravir/Rilpivirine	13	$43,393
TriumeqAbacavir/Dolutegravir/Lamivudi	12	$42,136
TivicayDolutegravir Sodium	16	$33,704
EliquisApixaban	51	$29,231
JanuviaSitagliptin Phosphate	31	$17,693
TrulicityDulaglutide	14	$13,950
JardianceEmpagliflozin	20	$13,583
Incruse ElliptaUmeclidinium Bromide	38	$12,787
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	25	$11,299
Breo ElliptaFluticasone/Vilanterol	25	$9,584
Advair HfaFluticasone Propion/Salmeterol	25	$7,996
Arnuity ElliptaFluticasone Furoate	32	$7,804
Albuterol Sulfate HfaAlbuterol Sulfate	233	$7,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GileadBiktarvy	$2,365	$200,41252 claims
Viiv Healthcare CompanyJuluca, Triumeq, Tivicay	$2,189	$119,23341 claims
GSKIncruse Ellipta, Breo Ellipta, Arnuity Ellipta	$11	$30,17595 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 799 infectious disease providers in New York.

Other infectious disease in New York

Wafaa El SadrNew York$119.1M
Judith AbergNew York$14.8M
Magdalena SobieszczykNew York$2.9M
Kristen MarksNew York$2.8M
Genovefa PapanicolaouNew York$2.7M
Thomas WalshNew York$1.4M
Sean LiuNew York$1.4M
Martin MarkowitzNew York$1.4M
Angelica KottkampNew York$1.2M
Michelle CespedesNew York$819K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →